



Fig. S1. Sensitivity analysis of relative contribution of itch and Psoriasis Area and Severity Index (PASI) scores on Dermatology Life Quality Index (DLQI) symptom and feelings domain score change at Week 4 and Week 12. ETN: etanercept; IXE Q2W: ixekizumab 80mg once every 2 weeks; IXE Q4W: ixekizumab 80mg once every 4 weeks; PBO: placebo.